BCYC
Bicycle TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
BCYC Profile
Bicycle Therapeutics Plc
A clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics
Pharmaceutical
10/27/2017
05/23/2019
NASDAQ Stock Exchange
305
12-31
Depository Receipts (Ordinary Shares)
Blocks A & B, Portway Building, Granta Park, Great Abington, Cambridge, United Kingdom, CB21 6GS
--
Bicycle Therapeutics plc was incorporated under the laws of England and Wales on 27 October 2017. The company is a clinical-stage biopharmaceutical company developing a new class of drugs, which they call bicycles, for diseases for which existing treatments are insufficient. Bicycles are fully synthetic short peptides that limit the formation of two rings, stabilizing their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targeting of drugs, which has historically been difficult to handle with non-biological methods. Bicycles are a unique treatment that combines pharmacology, usually associated with biological agents, with the manufacture and pharmacokinetic or PK properties of small molecules.
